-
JBCRG-C01
Observational study to evaluate the usefulness of trastuzumab as adjuvant therapy in patients with HER2 positive primary breast cancer: Cohort I
- Status
-
Study Closed
- Objectives
-
To evaluate the efficacy and safety of trastuzumab used as adjuvant therapy for operable breast cancer (Early Breast Cancer: EBC) in clinical settings in Japan
- Subjects
-
- Endpoints
-
Primary endpoint: Disease Free Survival, Secondary endpoint: Overall Survival, Safety
- Trial Period
-
July 2009 - June 2014
- Lead Principal Investigator
-
Hiroyasu Yamashiro(Dept of Breast surgery, Kyoto University Hospital)
- Target Sample Size
-
1500
- Regimen
-
- Source of Funding
-
JBCRG
- Conference Presentation
-
Safety of trastuzumab in HER2 positive primary breast cancer in Japan; Initial safety report for the large scale cohort study (JBCRG-C01)
Cohort study evaluating trastuzumab in HER2 positive early breast cancer in Japan; JBCRG-C01
- Articles and Publications
-
Outcomes of Trastuzumab Therapy in HER2-Positive Early Breast Cancer Patients: Extended Follow-up of JBCRG-Cohort Study 01
Outcomes of trastuzumab therapy in HER2‑positive early breast cancer patients (JBCRG-C01)
- UMIN-ID
-
UMIN000002737
- jRCT
-
- Memo
-
- COI Disclosure
-
